Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Age-related SA
Anti-VEGF
VF progression
 
 
Survey

Do you repeat SLT treatment more than twice in the same section of TM?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


April 9, 2014
Imaging and diagnostics
Shape and GRIN contribute to age-related SA
Internal limiting membrane (ILM) peeling surgery causes significant modification of retinal nerve fibre layer (RNFL) thickness, according to researchers at the Ophthalmology Units of the University of Bologna and the Sant’Orsola-Malpighi Polyclinic. More...
Retina therapy
Morphologic parameters affect anti-VEGF therapy outcome
Patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy to treat neovascular age-related macular degeneration (AMD) exhibit a distinct response pattern and time course of certain retinal morphologic changes. More...
Glaucoma research
Central VF progression faster in NTG with autonomic dysfunction
Central visual field (VF) progression is faster in patients with normal tension glaucoma (NTG) and lower heart-rate variability than it is in NTG patients with higher heart-rate variability, according to recently published research. More...
Product Profile
ZEISS Cataract Suite markerless
Align toric IOLs and skip the manual marking and data transfer steps with products designed to work together for markerless toric IOL alignment.
Read more
Event Profile
120th Congress of the French Society of Ophthalmology
Dates: 10–13 May 2014
Venue: Palais des Congrès, Porte Maillot, Paris
The SFO’s annual congress will bring together more than 8000 attendees, 100 exhibitors, 60 scientific sessions, 300 oral communications, 60 workshops, symposia with foreign Societies, 450 e-posters and e-films … Hot Topics will be discussed, a live surgery session on Monday 12th will be programmed, and a specific space (2nd floor) will be dedicated to technology and communication.
Read more:
Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy. Read more:
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: